Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial

Retrieved on: 2021-09-15 13:52:30

Tags for this article:

Click the tags to see associated articles and topics

Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial. View article details on hiswai:

Excerpt

Biogen said it plans to launch a trial to test a high dose of Spinraza in patients who've had prior treatment with a rival from Roche. (Biogen).

Article found on: www.fiercepharma.com